title: Do proton pump inhibitors protect against cancer progression in GERD?
abstract: Gastro-duodenal content reflux from gastro-esophageal reflux disease (GERD) induces the inflammation-metaplasia-dysplasia-adenocarcinoma sequence. Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, which are widely used for treating GERD and peptic ulcer-associated acid-secreting diseases. The effect of PPI therapy on esophageal carcinogenesis remains unclear. While some studies suggest PPIs result in a significant reduction in the risk of developing dysplasia and adenocarcinoma in patients with Barrett's esophagus, others suggest that PPIs have no effect. Recent studies have revealed that PPIs can exert anti-inflammatory effects such as anti-oxidant properties and immunomodulatory effects through their interactions with neutrophils, monocytes, endothelial and epithelial cells. In addition, PPIs have the ability to prevent adhesion molecule binding in malignant cells and suppress metastasis. This article reviews the role of PPIs in esophageal carcinogenesis and their use as antitumor agents.
authors.affiliation: Department of Gastroenterological Surgery, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan. tomoharumiya@gmail.com
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Miyashita
authors.forename: Furhawn A
authors.initials: FA
authors.lastname: Shah
authors.forename: John W
authors.initials: JW
authors.lastname: Harmon
authors.forename: Guy P
authors.initials: GP
authors.lastname: Marti
authors.forename: Daisuke
authors.initials: D
authors.lastname: Matsui
authors.forename: Koichi
authors.initials: K
authors.lastname: Okamoto
authors.forename: Isamu
authors.initials: I
authors.lastname: Makino
authors.forename: Hironori
authors.initials: H
authors.lastname: Hayashi
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Oyama
authors.forename: Hisatoshi
authors.initials: H
authors.lastname: Nakagawara
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Tajima
authors.forename: Hideto
authors.initials: H
authors.lastname: Fujita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takamura
authors.forename: Manabu
authors.initials: M
authors.lastname: Murakami
authors.forename: Itasu
authors.initials: I
authors.lastname: Ninomiya
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Sachio
authors.initials: S
authors.lastname: Fushida
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimura
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ohta
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000517:prevention & control*; D000818:Animals; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000975:Antioxidants; D001471:Barrett Esophagus / Q000150:complications / Q000188:drug therapy; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000209:etiology / Q000517:prevention & control*; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors; D064747:Lansoprazole; D009504:Neutrophils / Q000276:immunology; D009853:Omeprazole; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D064750:Rabeprazole
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000975:Antioxidants; D007155:Immunologic Factors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D009853:Omeprazole